AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19476398 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 0
Study 17463301 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe Intermittent Hypoxia (SIH) - 12% O2 for 1 h/day, 5 days/week for 8 weeks
Number of subjects: 20
Study 17463301 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intermittent Hypoxia (MIH) - 15% O2 for 1 h/day, 5 days/week for 8 weeks
Number of subjects: 20
Study 17463301 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 20
Study 15063421 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25 to 100 mg thrice daily)
Number of subjects: 22
Study 15063421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11568190 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) of the lumbar spine in 1989
Number of subjects: 50
Study 11568190 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat magnetic resonance imaging scans
Number of subjects: 50
Study 11568190 — intervention group
Group type: COMPARATOR
Intervention: Original MRI scans from 1989
Number of subjects: 50
Study 11055475 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30-60 mg)
Number of subjects: 186
Study 11055475 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5-10 mg)
Number of subjects: 186
Study 11055475 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 186
Study 11055475 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS and Enalapril
Number of subjects: 186
Study 9070958 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (50 mg) plus dipyridamole (150 mg/day)
Number of subjects: 1083
Study 9070958 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (50 mg) plus ticlopidine (200 mg/day)
Number of subjects: 1083
Study 9070958 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet agents (combined treatment)
Number of subjects: 1083
Study 9070958 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment group
Number of subjects: 1083
Study 8444627 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial aerobic capacity, depression, anxiety; changes in depression and social activity at 3 months
Number of subjects: 120
Study 8444627 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial anxiety and physical activity, change in depression, support of friends for exercise, exercise behavior at prior assessment at 9 months
Number of subjects: 120
Study 8444627 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial aerobic capacity, change in pain, exercise behavior at the two prior assessments at 18 or more months
Number of subjects: 120
Study 3723262 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice powder ORS (30 g/L of rice powder)
Number of subjects: 50
Study 3723262 — intervention group
Group type: COMPARATOR
Intervention: WHO recommended glucose ORS (20 g/L of glucose)
Number of subjects: 50
Study 3723262 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice powder ORS
Number of subjects: 50
Study 3723262 — intervention group
Group type: COMPARATOR
Intervention: WHO recommended glucose ORS
Number of subjects: 50
Study 29856344 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated varicella zoster vaccine (vaccine consistency lot group)
Number of subjects: 1230
Study 29856344 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated varicella zoster vaccine (high-antigen lot group)
Number of subjects: 1230
Study 29856344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1230
Study 29856344 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccine groups
Number of subjects: 1230
Study 29856344 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated varicella zoster vaccine
Number of subjects: 1230
Study 27632360 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-Based Health Coaching (TBHC)
Number of subjects: 6208
Study 24389524 — intervention group
Group type: EXPERIMENTAL
Intervention: High-light physical activity (HLPA): 2.1-2.9 METs
Number of subjects: 641
Study 24389524 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-light physical activity (LLPA): 1.5-2.0 METs
Number of subjects: 641
Study 24389524 — intervention group
Group type: COMPARATOR
Intervention: Moderate to vigorous physical activity (MVPA): ≥3.0 METs
Number of subjects: 641
Study 22453844 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep water running (DWR)
Number of subjects: 58
Study 22453844 — intervention group
Group type: COMPARATOR
Intervention: General practice (GP) alone
Number of subjects: 58
Study 20013055 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella supplementation (6 g daily from 12th-18th week of gestation until delivery)
Number of subjects: 70
Study 20013055 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella supplementation
Number of subjects: 70
Study 20013055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Chlorella supplementation)
Number of subjects: 70
Study 18725823 — intervention group
Group type: EXPERIMENTAL
Intervention: NetLET (personalized e-mail from physician) in private access group
Number of subjects: 97
Study 18725823 — intervention group
Group type: COMPARATOR
Intervention: Control group (mailed reminder letter from physician) in private access group
Number of subjects: 97
Study 18725823 — intervention group
Group type: COMPARATOR
Intervention: Control group (mailed reminder letter from physician) in public access group
Number of subjects: 97
Study 18725823 — intervention group
Group type: EXPERIMENTAL
Intervention: NetLET in public access group
Number of subjects: 97
Study 18725823 — intervention group
Group type: EXPERIMENTAL
Intervention: NetLET in private access group
Number of subjects: 97
Study 15692770 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive addition lenses
Number of subjects: 95
Study 12796667 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 1078
Study 12796667 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 1078
Study 12796667 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 1078
Study 12796667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1078
Study 10505808 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser at 3W power for 1 second
Number of subjects: 50
Study 10505808 — intervention group
Group type: COMPARATOR
Intervention: 6% hydrogen peroxide
Number of subjects: 50
Study 10505808 — intervention group
Group type: COMPARATOR
Intervention: EDTA solution (pH 7.4)
Number of subjects: 50
Study 10505808 — intervention group
Group type: COMPARATOR
Intervention: Saturated citric acid solution (pH 1)
Number of subjects: 50
Study 10505808 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser at 3W power for 0.2, 0.4, or 0.6 seconds
Number of subjects: 50
Study 10505808 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser at 3W power for 0.8 seconds
Number of subjects: 50
Study 10505808 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser at 3W power for 1.2 and 1.4 seconds
Number of subjects: 50
Study 9201757 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 72
Study 9201757 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 72
Study 9201757 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic patients with a history of long‐term institutionalization
Number of subjects: 72
Study 1757172 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive program of smoking control, discouragement, and cessation
Number of subjects: 0
Study 1757172 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation alone (control)
Number of subjects: 0
Study 30235286 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 multiantigen DNA vaccine (HIV-MAG, 3000 μg) co-administered with IL-12 plasmid DNA adjuvant (0, 250, 1000, or 1500 μg) via electroporation.
Number of subjects: 88
Study 30235286 — intervention group
Group type: EXPERIMENTAL
Intervention: VSV-Gag vaccine (3.4 ⊆ 107 PFU) given at 6 months after the initial vaccination.
Number of subjects: 88
Study 30235286 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 participants).
Number of subjects: 88
Study 27243762 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive training group that received 12 sessions of training covering 3 inhibitory processes
Number of subjects: 36
Study 27243762 — intervention group
Group type: COMPARATOR
Intervention: Active control group that received 4 sessions of mental health lectures
Number of subjects: 36
Study 27243762 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive training group
Number of subjects: 36
Study 24458074 — intervention group
Group type: EXPERIMENTAL
Intervention: Online hemodiafiltration
Number of subjects: 714
Study 24458074 — intervention group
Group type: COMPARATOR
Intervention: Low-flux hemodialysis
Number of subjects: 714
Study 22632452 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 50, 100, 200, 300 mg daily or 300 mg twice daily
Number of subjects: 198
Study 22632452 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Sitagliptin 100 mg daily
Number of subjects: 198
Study 22632452 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 198
Study 22632452 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Sitagliptin
Number of subjects: 198
Study 20562541 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration therapy (RelaWave; Matsuda Micronics Corp, Chiba, Japan) applied for 15 minutes 3 times a day for up to 7 days
Number of subjects: 31
Study 20562541 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care according to PrU care guidelines)
Number of subjects: 31
Study 20562541 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration therapy
Number of subjects: 31
Study 18097228 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG evidence of IHD detected in HIV-infected adults
Number of subjects: 4831
Study 18097228 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > or = 60 years
Number of subjects: 4831
Study 18097228 — intervention group
Group type: EXPERIMENTAL
Intervention: Current antihypertensive therapy
Number of subjects: 4831
Study 18097228 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment in Europe
Number of subjects: 4831
Study 18097228 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment in Asia
Number of subjects: 4831
Study 18097228 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 4831
Study 17259790 — intervention group
Group type: EXPERIMENTAL
Intervention: One daily GH injection
Number of subjects: 18
Study 17259790 — intervention group
Group type: COMPARATOR
Intervention: Two daily GH injections
Number of subjects: 18
Study 12716484 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-beta1b treatment (16 patients)
Number of subjects: 24
Study 12716484 — intervention group
Group type: COMPARATOR
Intervention: No treatment (8 patients)
Number of subjects: 24
Study 12716484 — intervention group
Group type: EXPERIMENTAL
Intervention: MS patients (both groups)
Number of subjects: 24
Study 12716484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 10764849 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncorrected visual acuity 0.5 (20/40) or worse in at least one eye
Number of subjects: 6134
Study 10764849 — intervention group
Group type: EXPERIMENTAL
Intervention: Presenting visual acuity 0.5 (20/40) or worse in at least one eye
Number of subjects: 6134
Study 10764849 — intervention group
Group type: EXPERIMENTAL
Intervention: Best visual acuity 0.5 or worse in both eyes
Number of subjects: 6134
Study 10764849 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractive error as a cause of reduced vision
Number of subjects: 6134
Study 10764849 — intervention group
Group type: EXPERIMENTAL
Intervention: Amblyopia as a cause of reduced vision
Number of subjects: 6134
Study 10764849 — intervention group
Group type: EXPERIMENTAL
Intervention: Other causes of reduced vision
Number of subjects: 6134
Study 10764849 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexplained causes of reduced vision
Number of subjects: 6134
Study 10764849 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopia prevalence in 15-year-old females
Number of subjects: 6134
Study 10764849 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopia prevalence in 15-year-old males
Number of subjects: 6134
Study 10764849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperopia 2 diopters or greater in 5-year-old males
Number of subjects: 6134
Study 10764849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperopia 2 diopters or greater in 5-year-old females
Number of subjects: 6134
Study 10764849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperopia 2 diopters or greater in 15-year-olds
Number of subjects: 6134
Study 9165428 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous phenytoin (PHT) - two infusions (mean dosage of 18 mg/kg; mean time of 1 hr)
Number of subjects: 66
Study 9165428 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous phenytoin (PHT) - one infusion
Number of subjects: 66
Study 9165428 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study 1560798 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol (80 mg per kilogram of body weight per day)
Number of subjects: 221
Study 1560798 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol
Number of subjects: 221
Study 1560798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 4091994 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin 0.5 g
Number of subjects: 12
Study 4091994 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 120 mg
Number of subjects: 12
Study 4091994 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 240 mg
Number of subjects: 12
Study 4091994 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 12
Study 4091994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30671805 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel group
Number of subjects: 72
Study 30671805 — intervention group
Group type: COMPARATOR
Intervention: Clamp-crush group
Number of subjects: 72
Study 29934764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecc‐vBFR
Number of subjects: 36
Study 29934764 — intervention group
Group type: EXPERIMENTAL
Intervention: Con‐vBFR
Number of subjects: 36
Study 29934764 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 29934764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecc‐vBFR and Con‐vBFR
Number of subjects: 36
Study 26868727 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive care (≥1 asthma maintenance visit/year)
Number of subjects: 948
Study 26868727 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute care (≥1 acute asthma visit/year)
Number of subjects: 948
Study 24534386 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 Modic changes
Number of subjects: 141
Study 24534386 — intervention group
Group type: COMPARATOR
Intervention: Type 2 Modic changes
Number of subjects: 141
Study 24534386 — intervention group
Group type: COMPARATOR
Intervention: Other degenerative manifestations
Number of subjects: 141
Study 22932714 — intervention group
Group type: EXPERIMENTAL
Intervention: Trevo Retriever
Number of subjects: 178
Study 22932714 — intervention group
Group type: COMPARATOR
Intervention: Merci Retriever
Number of subjects: 178
Study 20171422 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (dispersible tablets) of MMF 1.0 g
Number of subjects: 18
Study 20171422 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (capsules) of MMF 1.0 g
Number of subjects: 18
Study 17607437 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) with 24 blocks (Group 1)
Number of subjects: 45
Study 17607437 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) with 36 blocks (Group 2)
Number of subjects: 45
Study 17607437 — intervention group
Group type: COMPARATOR
Intervention: Control group with zero current intensity stimulation
Number of subjects: 45
Study 16141440 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air resuscitation (RAR)
Number of subjects: 0
Study 16141440 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen resuscitation (OxR)
Number of subjects: 0
Study 16141440 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonasphyctic term newborns)
Number of subjects: 0
Study 12173198 — intervention group
Group type: COMPARATOR
Intervention: 0.10% bupivacaine plus sufentanil 0.5 microgram ml-1
Number of subjects: 140
Study 12173198 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% ropivacaine plus sufentanil 0.5 microgram ml-1
Number of subjects: 140
Study 10460553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.039 mg.kg‐1 bolus + 0.215 mg.kg‐1.h‐1 infusion)
Number of subjects: 6
Study 10460553 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (0.05 mg.kg‐1 bolus + 0.275 mg.kg‐1.h‐1 infusion)
Number of subjects: 6
Study 8849209 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectric impedance (BI) at 1 kHz
Number of subjects: 28
Study 8849209 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectric impedance (BI) at 100 kHz
Number of subjects: 28
Study 2211752 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar plexus block with bupivacaine
Number of subjects: 20
Study 2211752 — intervention group
Group type: COMPARATOR
Intervention: No lumbar plexus block
Number of subjects: 20
Study 339846 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied caffeine 30%-hydrocortisone 0.5% in hydrophilic ointment
Number of subjects: 83
Study 339846 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate 0.1% cream
Number of subjects: 83
Study 339846 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 0.5% in hydrophilic ointment
Number of subjects: 83
Study 30140069 — intervention group
Group type: EXPERIMENTAL
Intervention: Late surfactant treatment
Number of subjects: 209
Study 30140069 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surfactant treatment)
Number of subjects: 209
Study 28697127 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg orally 1 hour before ERCP
Number of subjects: 170
Study 28697127 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion only (control group)
Number of subjects: 170
Study 25613468 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA testing (intervention arm)
Number of subjects: 415000
Study 25613468 — intervention group
Group type: COMPARATOR
Intervention: NHS prostate cancer risk management programme (control arm)
Number of subjects: 415000
Study 24045411 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready for Recess
Number of subjects: 98
Study 24045411 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 98
Study 24045411 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention assessment
Number of subjects: 98
Study 22175055 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 L polyethylene glycol (PEG)
Number of subjects: 834
Study 22175055 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 L PEG + 20 mg bisacodyl
Number of subjects: 834
Study 22175055 — intervention group
Group type: COMPARATOR
Intervention: 90 mL of sodium phosphate (NaP)
Number of subjects: 834
Study 22175055 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMC + 300 mL of magnesium citrate (M)
Number of subjects: 834
Study 18710606 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (400 mg capsules, twice daily for 8 weeks)
Number of subjects: 88
Study 18710606 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose, twice daily for 8 weeks)
Number of subjects: 88
Study 18710606 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG
Number of subjects: 88
Study 18710606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 16359745 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol (4 drink equivalent)
Number of subjects: 55
Study 16359745 — intervention group
Group type: COMPARATOR
Intervention: 0.4 g/kg alcohol (2 drink equivalent)
Number of subjects: 55
Study 16359745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 12540352 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised inpatient rehabilitation in an orthopaedic hospital (Group A)
Number of subjects: 145
Study 12540352 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised inpatient rehabilitation in a geriatric hospital (Group B)
Number of subjects: 145
Study 12540352 — intervention group
Group type: COMPARATOR
Intervention: No special rehabilitation, directly discharged home (Control Group C)
Number of subjects: 145
Study 12540352 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 145
Study 10548187 — intervention group
Group type: EXPERIMENTAL
Intervention: CBF-targeted protocol
Number of subjects: 189
Study 10548187 — intervention group
Group type: COMPARATOR
Intervention: ICP-targeted protocol
Number of subjects: 189
Study 10548187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 189
Study 8752791 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department‐based rapid rule‐out protocol (n = 50)
Number of subjects: 100
Study 8752791 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital care (n = 50)
Number of subjects: 100
Study 8752791 — intervention group
Group type: COMPARATOR
Intervention: Historical control subjects (n = 160)
Number of subjects: 100
Study 1853495 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 160
Study 1853495 — intervention group
Group type: COMPARATOR
Intervention: Opioid (Pentazocine)
Number of subjects: 160
Study 1853495 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 160
Study 6395526 — intervention group
Group type: EXPERIMENTAL
Intervention: Bencyclan (2x 200 mg daily for 8 weeks)
Number of subjects: 50
Study 6395526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6395526 — intervention group
Group type: EXPERIMENTAL
Intervention: Bencyclan
Number of subjects: 50
Study 31672177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 1-month DAPT
Number of subjects: 15991